New pill aims to tame rheumatoid arthritis pain and swelling

NCT ID NCT07408024

Recruiting now Disease control Sponsor: Toll Biotech Co. Ltd. (Beijing) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new oral drug, TollB-001, in 24 adults aged 18-70 with moderate to severe active rheumatoid arthritis who haven't responded well to standard treatments. Participants take either the drug or a placebo once daily for 4 weeks, with a 1-week follow-up. The goal is to check safety and see if it improves symptoms like joint pain and swelling.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS (RA)

Contacts and locations

Locations

Affiliated Hospital of Inner Mongolia Medical University
RECRUITING

Hohhot, Inner Mongolia, China
Linfen Central Hospital
RECRUITING

Linfen, Shanxi, China
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 102206, China
Pingxiang People's Hospital
RECRUITING

Pingxiang, Jiangxi, China
Puyang Oilfield General Hospital
RECRUITING

Puyang, Henan, China
The First Affiliated Hospital of Bengbu Medical College
RECRUITING

Bengbu, Anhui, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.